In view of the above, in this study we aimed to determine the role of serum ET-1 as a biomarker of ILD, as well as its use for the differential diagnosis between IPF and AD-ILD, using a large and well-defined cohort of patients with ILD. This evidence concerns the gene EDN1 and idiopathic pulmonary fibrosis.